Interestingly, three patients with BAP1 wild-type uveal melanoma had disease response, suggesting that the immunomodulatory function of HDAC inhibitors may be the predominant contributing function in anti-tumoral activity. The gene discussed is BAP1; the disease is uveal melanoma.